Residue-resolved insights into the stabilization of therapeutic proteins by excipients: A case study of two monoclonal antibodies with arginine and glutamate
Protein formulation development relies on the selection of excipients that inhibit protein–protein interactions preventing aggregation. Empirical strategies involve screening many excipient and buffer combinations by physicochemical characterization using forced degradation or temperature-induced st...
Saved in:
Main Authors: | Tobias M. Prass, Patrick Garidel, Lars V. Schäfer, Michaela Blech |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2427771 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies
by: Kristina M.J. Aertker, et al.
Published: (2024-12-01) -
Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling
by: Eliott Park, et al.
Published: (2024-12-01) -
IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria
by: Luis Felipe Ensina, et al.
Published: (2025-01-01) -
Reduction of monoclonal antibody viscosity using interpretable machine learning
by: Emily K. Makowski, et al.
Published: (2024-12-01) -
The Significance of Eosinophil-to-Lymphocyte Ratio in Predicting Response to Omalizumab Treatment in Patients with Bullous Pemphigoid: A Case Series
by: Gülfem Akin, et al.
Published: (2024-01-01)